Protection of bone marrow cells from toxicity of chemotherapeutic agents targeted toward thymidylate synthase by transfer of mutant forms of human thymidylate synthase cDNA

Progress in Experimental Tumor Research

Volumn 36, Issue , 1999, Pages 107-114

  Banerjee, Debabrata ^a   Tong, Youzhi ^a   Liu Chen, Xinyue ^a   Capiaux, Gina ^a   Ercikan Abali, Emine A ^a   Takebe, Naoko ^a   O'Connor, Owen A ^a   Bertino, Joseph R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; THYMIDYLATE SYNTHASE;

BONE MARROW CELL; DRUG EFFECT; GENE TRANSFER; GENETICS; HUMAN; MUTATION; REVIEW;

ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; DNA, COMPLEMENTARY; GENE TRANSFER TECHNIQUES; HUMANS; MUTATION; THYMIDYLATE SYNTHASE;

EID: 0032611951     PISSN: 00796263     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000061991     Document Type: Article

References (29)

1. Hryniuk W, Busch H: The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984;2:1281-1288.
2. Bierman PJ, Bagin RG, Jagannath S, Vose JM, Spitzer G, Kessinger A, Dicke KA, Armitage JO: High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: Long-term follow-up in 128 patients. Ann Oncol 1993;4:767.
3. Ellis GK, Hutchins L, Jimenez-Martin M, Pecora AL, Barnabas A, Meisenberg B, Nabholtz JM, Cortes-Funes H, Rifkin R, Chang AYC, Garrison L, George C, Giles FJ: Phase III double blind randomized study of PIXY321 versus G-CSF after CEP for breast or ovarian carcinoma. Blood 1996;88:449a.
4. Hofstra LS, Trope CG, Willemse PBH, Vindevoghel A, van den Bulche JM, Lahouseny M, Sklenar I, de Vries EGE: Randomized trial of rhIL-3 versus placebo in prevention of bone marrow depression during first-line chemotherapy for ovarian carcinoma. Proceedings ASCO 1997;16:115a.
5. Petzer AL, Zandstra PW, Piret JM, Eaves CJ: Differential cytokine effects on primitive (CD34 4- CD38 -) human hematopoietic cells: Novel responses to Flt-3 ligand and thrombopoietin. J Exp Med 1996;183:2551-2558.
6. Banerjee D, Zhao SC, Li M-X, Schweitzer BI, Mineishi S, Bertino JR: Gene therapy utilizing drug resistant genes. A review. Stem Cells 1994;12:378-384.
7. Miller AD: Progress toward human gene therapy. Blood 1990;76:271-278.
8. Koc ON, Allay JA, Lee K, Davis BM, Reese JS Gerson SL: Transfer of drug resistance genes into hematopoietic progenitors to improve chemotherapy tolerance. Semin Oncol 1996;23:46-65.
9. Bertino JR: Ode to methotrexate. J Clin Oncol 1993;11:5-14.
10. Williams DA, Hsieh K, DeSilva A, Mulligan RC: Protection of bone marrow transplant recipients from lethal doses of methotrexate by the generation of methotrexate resistant bone marrow. J Exp Med 1987;166:210-218.
11. Corey CA, DeSilva AD, Holland CA, Williams DA: Serial transplantation of methotrexate resistant bone marrow; protection of murine recipients from drug toxicity by progeny of transduced stem cells. Blood 1990;76:337-343.
12. May C, Gunther R, Mclvor RS: Protection of mice from lethal doses of methotrexate by transplantation with transgenic bone marrow expressing drug resistant dihydrofolate reductase activity. Blood 1995;86:2439-2448.
13. Zhao SC, Li M-X, Banerjee D, Schweitzer BI, Mineishi S, Gilboa E, Bertino JR: Long term protection of recipient mice from lethal doses of methotrexate by marrow infected with a double copy vector retrovirus containing a mutant dihydrofolate reductase. Cancer Gene Ther 1994;1:27-33.
14. Li M-X, Banerjee D, Zhao SC, Schweitzer BI, Mineishi S, Gilboa E, Bertino JR: Development of a retroviral construct containing a human mutated dihydrofolate reductase cDNA for hematopoietic stem cell transduction. Blood 1994;83:3403-3408.
15. Sorrentino BP, Brandt SJ, Bodine D, Gottesman M, Pastan I, Cline A, Nienhuis AW: Selection of drug resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 1992; 257:99-103.
16. Podda S, Ward M, Himelstein A, Richardson C, de la Flor-Weiss E, Smith L, Gottesman M, Pastan I: Transfer and expression of the human multiple drug resistance gene into live mice. Proc Natl Acad Sci USA 1992;89:9676-9680.
17. Gottesman MM, Germann UA, Aksentijevich I, Sugimoto Y, Cardarelli CO, Pastan I: Gene transfer of drug resistant genes. Implications for cancer therapy. Ann NY Acad Sci 1994;716:126-138.
18. + cells. Blood 1994;84:1408-1414.
19. Momparler RL, Eliopoulos N, Bovenzi V, Letourneau S, Greenbaum M, Cournoyer D: Resistance to cytosine arabinoside by retrovirally mediated gene transfer of human cytidine deaminase into murine fibroblast and hematopoietic cells. Cancer Gene Ther 1996;3:331-338.
20. Neff T, Blau CA: Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine. Exp Hematol 1996;24:1340-1346.
21. Moritz T, Mackay W, Glassner BJ, Williams DA, Samson L: Retrovirus mediated expression of a DNA repair protein in bone marrow protects hematopoietic cells from nitrosourea induced toxicity in vitro and in vivo. Cancer Res 1995;55:2608-2611.
22. Magni M, Shammah S, Schiro R, Mellado W, Dalla-Favera R, Gianni AM: Induction of cyclophosphamide resistance by aldehyde dehydrogenase gene transfer. Blood 1996;87:1097-1103.
23. Zhao SC, Banerjee D, Mineishi S, Bertino JR: Post transplant methotrexate administration leads to improved curability of mice bearing a mammary tumor transplanted with marrow transduced with a mutant human dihydrofolate reductase cDNA. Hum Gene Ther 1997;8:903-909.
24. Bertino JR, Li WW, Lin J, Trippelt T, Goker E, Schweitzer BI, Banerjee D: Enzymes of the thymidylate cycle as targets for chemotherapeutic agents. Mechanisms of resistance. Mt Sinai J Med 1992;59:391-395.
25. Hughey CT, Barbour KW, Berger EG, Berger SH: Functional effects of a naturally occurring amino acid substitution in human thymidylate synthase. Mol Pharmacol 1993;44:316-323.
26. Frantz C Spencer HT: Retroviral gene transfer of a thymidylate synthase-dihydrofolate reductase chimera confers fluoropyrimidine and antifolate resistance. 39th Annual Meeting, American Society of Hematology, San Diego. Blood 1997;90:4599a.
27. Tong Y, Chen X-L, Ercikan-Abali EA, Capiaux GM, Zhao SC, Banerjee D, Bertino JR: Isolation and characterization of Thymitaq and 5-fluoro-2-deoxyuridylate (FdUMP)- resistant mutants of human thymidylate reductase from ethylmethane sulfonate-exposed human sarcoma HT1080 cells. J Biol Chem 1998;273:11611-11618.
28. Tong Y, Chen X-L, Ercikan-Abali EA, Capiaux GM, Zhao SC, Banerjee D, Maley F, Bertino JR: Probing the binding site of human thymidylate synthase by site directed mutagenesis. Evidence that Tomudex, Thymitaq and BW1843U89 bind differently to this enzyme. J Biol Chem 1998;273: 31209-31214.
29. Riviere I, Sadelain M: Methods for the construction of retroviral vectors and the generation of high-liter producers; in Robbins P (ed): Methods in Molecular Medicine. Gene Therapy Protocols. Tolowa, Humana Press, 1997, pp 59-78.